AR075247A1 - Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparacion y su aplicacion en terapeutica - Google Patents

Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparacion y su aplicacion en terapeutica

Info

Publication number
AR075247A1
AR075247A1 ARP100100315A ARP100100315A AR075247A1 AR 075247 A1 AR075247 A1 AR 075247A1 AR P100100315 A ARP100100315 A AR P100100315A AR P100100315 A ARP100100315 A AR P100100315A AR 075247 A1 AR075247 A1 AR 075247A1
Authority
AR
Argentina
Prior art keywords
group
cycloalkyl
alkyl
cycle
alkylene
Prior art date
Application number
ARP100100315A
Other languages
English (en)
Inventor
Philippe Yaiche
Nathalie Chereze
Alistair Lochead
Mourad Saady
Ahmed Abouabdellah
Julien Vache
Aude Fayol
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR075247A1 publication Critical patent/AR075247A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composicion farmacéutica, proceso de preparacion y uso como inhibidores de la enzima FAAH. Reivindicacion 1: Compuesto que responde a la formula (1) en la que R2 representa un átomo de hidrogeno, de fluor o un grupo hidroxilo, ciano, trifluorometilo, alquilo C1-6, alcoxi C1-6, NR8R9; rn, n, o y p representan, independientemente entre sí, un numero entero igual a 0, 1, 2 o 3; A representa un enlace covalente o un grupo alquileno C1-8; R1 representa un grupo R5 opcionalmente sustituido por uno o varios grupos R6 y/o R7; R5 representa un grupo elegido entre un fenilo, piridinilo, piridazinilo, pirimidinilo, pirazinilo, triazinilo, naftalenilo, quinolinilo, isoquinolinilo, ftalazinilo, quinazolinilo, quinoxalinilo, cinolinilo, naftiridinilo; R6 representa un átomo de halogeno, un grupo ciano, -CH2CN, nitro, hidroxilo, alquilo C1-6, alcoxi C1-6, tioalquilo C1-6, haloalquilo C1-6, haloalcoxi C1-6, halotioalquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-3, cicloalquil C3-7-alquilen C1-3-O-, NR8R9, NR8COR9, NR8CO2R9, NR8SO2R9, NR8SO2NR8R9, COR8, CO2R8, CONR8R9, SO2R8, SO2NR8R9 u -O-alquilen C1-3-O-; R7 representa un grupo elegido entre un: furanilo, pirrolilo, tienilo, oxazolilo, isoxazolilo, tiazolilo, isotiazolilo, imidazolilo, pirazolilo, oxadiazol, tiadiazol, fenilo, piridinilo, piridazinilo, pirimidinilo, pirazinilo, triazina, naftalenilo, quinolinilo, isoquinolinilo, ftalazinilo, quinazolinilo, quinoxalinilo, cinnolinilo, naftiridinilo, imidazopirimidinilo, tienopirimidinilo, benzofuranilo, benzotienilo, bencimidazolilo, benzoxazolilo, bencisoxazolilo, benzotiazolilo, bencisotiazolilo, indolilo, isoindolilo, indazolilo, pirrolopiridinilo, furopiridinilo, tienopiridinilo, imidazopiridinilo, pirazolopiridinilo, oxazolopiridinilo, isoxazolopiridinilo, tiazolopiridinilo, feniloxi, benciloxi, pirimidinoxi; pudiendo estar el o los grupos R7 sustituidos por uno o varios grupos R6 idénticos o diferentes entre sí; R3 representa un átomo de hidrogeno, de fluor, un grupo alquilo C1-6 o un grupo trifluorometilo; R4 representa un grupo elegido entre un: furanilo, pirrolilo, tienilo, tiazolilo, isotiazolilo, oxazolilo, isoxazolilo, pirazolilo, oxadiazolilo, tiadiazolilo, imidazolilo, triazolilo, tetrazolilo; estando este grupo opcionalmente sustituido por uno o varios sustituyentes elegidos entre un átomo de halogeno, un grupo alquilo C1-6, haloalquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-3, haloalcoxi C1-6, ciano, NR8R9, NR8COR9, NR8CO2R9, NR8SO2R9, NR8SO2NR8R9, COR8, CO2R8, CONR8R9, CON(R8)alquilen C1-3-NR10R11, SO2R8, SO2NR8R9 u -O-alquilen C1-3-O-; fenilo, feniloxi, benciloxi, piridinilo, pirazinilo, piridazinilo, triazinilo o pirimidinilo; pudiendo estar los grupos fenilo, feniloxi, benciloxi, piridinilo, pirazinilo, piridazinilo, triazinilo y pirimidinilo sustituidos por uno o varios sustituyentes elegidos entre un átomo de halogeno, un grupo ciano, nitro, alquilo C1-6, alcoxi C1-6, tioalquilo C1-6, haloalquilo C1-6, haloalcoxi C1-6, halotioalquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-3; R8 y R9 representan, independientemente entre sí, un átomo de hidrogeno o un grupo alquilo C1-6, o forman con el o los átomos a los que están unidos, en el caso de NR8R9, un ciclo elegido entre los ciclos: azetidina, pirrolidina, piperidina, morfolina, tiomorfolina, azepina, oxazepina o piperazina, estando este ciclo opcionalmente sustituido por un grupo alquilo C1-6 o bencilo; en el caso de NR8COR9, un ciclo lactama; en el caso de NR8CO2R9, un ciclo oxazolidinona, oxazinona u oxazepinona; en el caso de NR8SO2R9, un ciclo sultame; en el caso de NR8SO2NR8R9, un ciclo dioxido de tiazolidina o dioxido de tiadiazinano; R10 y R11 representan, independientemente entre sí, un átomo de hidrogeno o un grupo alquilo C1-6 en el estado de base o de sal de adicion a un ácido.
ARP100100315A 2009-02-05 2010-02-05 Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparacion y su aplicacion en terapeutica AR075247A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0900493A FR2941696B1 (fr) 2009-02-05 2009-02-05 Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
AR075247A1 true AR075247A1 (es) 2011-03-16

Family

ID=41037747

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100315A AR075247A1 (es) 2009-02-05 2010-02-05 Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparacion y su aplicacion en terapeutica

Country Status (20)

Country Link
US (1) US8889702B2 (es)
EP (1) EP2393809B1 (es)
JP (1) JP5586632B2 (es)
KR (1) KR20110117215A (es)
CN (1) CN102369200B (es)
AR (1) AR075247A1 (es)
AU (1) AU2010212235B2 (es)
BR (1) BRPI1007456A2 (es)
CA (1) CA2751481C (es)
CO (1) CO6362007A2 (es)
EA (1) EA201171000A1 (es)
FR (1) FR2941696B1 (es)
IL (1) IL214390A0 (es)
MA (1) MA33104B1 (es)
MX (1) MX2011008308A (es)
SG (1) SG173557A1 (es)
TN (1) TN2011000331A1 (es)
TW (1) TW201039823A (es)
UY (1) UY32423A (es)
WO (1) WO2010089510A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130150346A1 (en) 2010-01-08 2013-06-13 Quest Ventures Ltd. Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
US20130224151A1 (en) 2010-03-31 2013-08-29 United States Of America Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
SI2820008T1 (sl) 2012-03-02 2017-06-30 Genentech, Inc. Amido-spirociklični amidni in sulfonamidni derivati
EP2903985A1 (en) * 2012-10-03 2015-08-12 Advinus Therapeutics Limited Spirocyclic compounds, compositions and medicinal applications thereof
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CN105899493B (zh) 2014-01-17 2019-03-29 诺华股份有限公司 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
ES2699351T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
WO2016203404A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
JP6878316B2 (ja) 2015-06-19 2021-05-26 ノバルティス アーゲー Shp2の活性を阻害するための化合物および組成物
JP6718889B2 (ja) 2015-06-19 2020-07-08 ノバルティス アーゲー Shp2の活性を阻害するための化合物および組成物
US20190083460A1 (en) * 2016-03-16 2019-03-21 Zeno Royalties & Milestones, LLC Analgesic compounds
CA3023216A1 (en) 2016-06-14 2017-12-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
WO2018130928A1 (en) 2017-01-10 2018-07-19 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
JOP20200023A1 (ar) 2017-08-29 2020-02-02 Lundbeck La Jolla Research Center Inc مركبات حلقية لولبية وطرق تصنيعها واستخدامها

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE184603T1 (de) 1991-06-19 1999-10-15 Pfizer Azaspirochinolone als antibakterielle wirkstoffe
AU3784997A (en) 1996-08-09 1998-03-06 Eisai Co. Ltd. Benzopiperidine derivatives
PL339836A1 (en) 1998-02-19 2001-01-02 Eisai Co Ltd Phtalazine compounds and therapeutic agents suitable to treat erection disorders
FR2816938B1 (fr) 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
JP2003246780A (ja) 2001-12-17 2003-09-02 Eisai Co Ltd 含窒素芳香環化合物の製造方法
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
FR2843964B1 (fr) * 2002-08-29 2004-10-01 Sanofi Synthelabo Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
US7176201B2 (en) * 2002-10-07 2007-02-13 The Regents Of The University Of California Modulation of anxiety through blockade of anandamide hydrolysis
FR2854633B1 (fr) * 2003-05-07 2005-06-24 Sanofi Synthelabo Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique
FR2866885B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique
FR2885364B1 (fr) * 2005-05-03 2007-06-29 Sanofi Aventis Sa Derives d'alkyl-, alkenyl-et alkynylcarbamates, leur preparation et leur application en therapeutique
EP2069356A1 (en) 2006-07-24 2009-06-17 Gilead Sciences, Inc. Bisfuranyl protease inhibitors
TW200831080A (en) * 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
FR2934265B1 (fr) * 2008-07-23 2010-07-30 Sanofi Aventis Derives de carbamates d'alkylthiazoles, leur preparation et leur application en therapeutique
US20100113465A1 (en) * 2008-10-30 2010-05-06 Pfizer Inc. 7-azaspiro[3.5]nonane-7-carboxamide compounds

Also Published As

Publication number Publication date
MX2011008308A (es) 2011-11-02
EP2393809A2 (fr) 2011-12-14
CA2751481C (fr) 2017-05-23
CN102369200A (zh) 2012-03-07
FR2941696B1 (fr) 2011-04-15
TN2011000331A1 (fr) 2013-03-27
FR2941696A1 (fr) 2010-08-06
US8889702B2 (en) 2014-11-18
EP2393809B1 (fr) 2014-04-30
CN102369200B (zh) 2015-05-20
AU2010212235B2 (en) 2016-06-09
BRPI1007456A2 (pt) 2019-04-16
EA201171000A1 (ru) 2012-02-28
SG173557A1 (en) 2011-09-29
CA2751481A1 (fr) 2010-08-12
WO2010089510A3 (fr) 2010-09-30
JP2012516881A (ja) 2012-07-26
IL214390A0 (en) 2011-09-27
JP5586632B2 (ja) 2014-09-10
TW201039823A (en) 2010-11-16
US20110319381A1 (en) 2011-12-29
CO6362007A2 (es) 2012-01-20
UY32423A (es) 2010-09-30
MA33104B1 (fr) 2012-03-01
KR20110117215A (ko) 2011-10-26
AU2010212235A1 (en) 2011-08-25
WO2010089510A2 (fr) 2010-08-12

Similar Documents

Publication Publication Date Title
AR075247A1 (es) Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparacion y su aplicacion en terapeutica
AR072593A1 (es) DERIVADOS DE ALQUILTIAZOLES, SU PREPARACIoN, COMPOSICIONES FARMACEUTICA QUE LOS CONTIENEN Y SU USO COMO INHIBIDORES DE LA ENZIMA FAAH
AR076562A1 (es) Derivados de ciclopenta (c) pirrol-2- carboxilatos, su preparacion y su aplicacion en terapeutica
AR076563A1 (es) Derivados de ciclopenta[c]pirrol-2-carboxilatos, su preparacion y su apli-cacion en terapeutica
AR074119A1 (es) Derivados de carbamatos de alquil-heterociclos, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos en el tratamiento de enfermedades neurologicas,infecciosas y gastrointestinales, entre otras.
AR076561A1 (es) Derivados de ciclopenta (c) pirrol-2- carboxilatos, su preparacion y su aplicacion en terapeutica
AR044178A1 (es) Derivados de piperidinil- y piperazinil-alquilcarbamatos, su preparacion y su aplicacion en terapeutica
PE20091974A1 (es) Derivados de indazoles sustituidos con fenil o piridinilo
AR067444A1 (es) Derivados de pirazinona, procesos de obtencion y composiciones farmaceuticas
AR047818A1 (es) Derivados de piperidinilalquilcarbamatos, su preparacion y su aplicacion en terapeutica
AR054882A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
UY30603A1 (es) Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion y su aplicacion en terapéutica
NI200800036A (es) Inhibidores macrociclicos del virus de la hepatitis c
HRP20080024T3 (en) Derivatives of alkylpiperazine- and alkylhomopiperazine- carboxylates, preparation method thereof and use of same as faah enzyme inhibitors
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
AR070995A1 (es) Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridina,composiciones farmaceuticas que los contienen, proceso de preparacion de los mismos, intermediarios de sintesis y uso de los mismos en el tratamiento o prevencion de enfermedades que implican receptores nucleares nurr-1,tales como enfe
AR047384A1 (es) Derivados de tipo ariloxialquilcarbamatos, su preparacion y su aplicacion en terapeutica
BRPI0612888A8 (pt) anilino-piridinotriazinas cíclicas
AR047817A1 (es) Derivados de aril- y heteroarilpiperidincarboxilatos, su preparacion y su aplicacion en terapeutica
PE20090595A1 (es) Derivados de quinoliniloxipiperidina y pirrolidina como antagonistas del receptor h1
PE20091433A1 (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procedimientos para su preparacion 177
AR066605A1 (es) Derivados de heteroarilamida pirimidona
AR042746A1 (es) Derivados de arilalquilcarbamatos, su preparacion y su aplicacion en terapeutica.
MX2010009092A (es) Nuevos derivados de 3-aminoalquil-1,3-dihidro-2h-indol-2-ona, su preparacion y su aplicacion en terapeutica.
AR071483A1 (es) Derivados de la 1,3- dihidro -2h - pirrolo (3,2-b) piridin-2- ona, su preparacion y sus aplicaciones en terapeutica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal